Shasun Chemicals and Drugs Limited

Activities: Manufacturing Ingredients Research & Development

Trending Articles

  1. Johnson & Johnson to bolster neuroscience portfolio with $14.6bn Intra-Cellular Therapies acquisition Through this potential acquisition, Johnson & Johnson will add schizophrenia and bipolar drug Caplyta to its portfolio, as well as a range of clinical candidates designed to...
  2. Lonza and Iconovo collaborate to develop intranasal biologic for obesity The two will aim to create an effective and stable inhaled formulation that can be used to treat obesity without the need for frequent injections
  3. Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Revolutionising drug delivery and advancing sustainability Capsule innovation and 3D printing will transform pharma for a future of precision and ethical solutions
  5. MM Pharma showcases its secondary packaging solutions at Pharmapack Europe 2025 Visitors to booth J85 can chat with technical experts about pharmaceutical packaging challenges and requirements, as well as how MM Pharma can help with their secondary...

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Finance

Strides Shasun acquires three OTC brands from Moberg Pharma

Indian firm is building an over-the-counter drug franchise in regulated and emerging markets
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Ingredients

Indian API market on the up as domestic drug prices fall

Indian API manufacturers are branching out into new markets, while international suppliers could be hit by lower prices in the domestic market, writes Asia correspondent A Nair
Ingredients

Indian pharma exports to be hit by Falsified Medicines Directive

API exporters say latest EU move is a non-issue
Subscribe now